In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- June 19, 2018 Development of a microRNA-155 inhibitor as a therapeutic for acute spinal cord injury New Frontiers in Neuroinflammation: What Happens When CNS and Periphery Meet?
- June 4, 2018 Phase 1 Study of Cobomarsen (MRG-106) in Cutaneous T cell Lymphoma and HTLV-1 associated T cell Leukemia/Lymphoma American Society of Clinical Oncology Annual Meeting
- May 9, 2018 cobomarsen (miR155 inhibitor) in CTCL/MF 2015…2018 T-Cell Lymphomas: we are close to the finalization
- May 2, 2018 Inhibition of ocular fibrosis with a miR-29b mimic 2018 Association for Research in Vision and Ophthalmology
- May 2, 2018 Restoring miRNAs of the miR-18396182 cluster ameliorates symptoms of retinal degeneration in a mouse model of retinitis pigmentosa 2018 Association for Research in Vision and Ophthalmology
- April 27, 2018 Improved Perfusion and Wound Healing in Healthy Pigs with MRG-110, an Inhibitor of microRNA-92a (Poster) 2018 Wound Healing Society Annual Meeting
- April 27, 2018 Improved Perfusion and Wound Healing in Healthy Pigs with MRG-110, an Inhibitor of microRNA-92a (Presentation) 2018 Wound Healing Society Annual Meeting
- February 2, 2018 Emerging rationale for targeting miRNAs in CTCL 2018 Annual T-Cell Lymphoma Forum
- December 11, 2017 Phase 1 Study of the Safety and Efficacy of MRG 106 a Synthetic Inhibitor of microRNA 155 in CTCL Patients American Society for Hematology Annual Meeting
- November 14, 2017 RNA Based Therapeutics as a Modality for the Effective Treatment of Multiple Fibrotic Conditions The 2017 Anti-Fibrotic Drug Development Summit